Rationale Melanin-concentrating hormone (MCH) is involved in regulation of appetitive behaviors as well as emotional reactivity and reward, behavioral domains relevant to alcohol addiction. Results Ex vivo binding experiments demonstrated that the GW803430 dose range used resulted in high central MCH1 receptor occupancy. Alcohol self-administration was dosedependently and potently suppressed, by approximately 80% at the highest dose. Reinstatement of alcohol-seeking induced by alcohol-associated cues was essentially eliminated. In contrast, reinstatement induced by footshock stress was not significantly altered. Taste preference for a quinine/saccharin solution, locomotor activity, and alcohol elimination were unaffected.
Introduction
Melanin-concentrating hormone was originally isolated from the pituitary of chum salmon as a 17-amino acid (a.a.) peptide hormone that induces aggregation of melanocytes, resulting in lightening of the skin (Kawauchi et al. 1983) . The homologous mammalian peptide is 19 a.a. and is fully conserved between rat and human. MCH is mainly expressed centrally and MCH-positive cell bodies are only found in the lateral hypothalamus and the zona incerta. However, MCH-containing neurons project throughout the brain (Bittencourt et al. 1992) , indicating that MCH may have a broader range of physiological roles. Two MCH receptor subtypes, MCH1-R and MCH2-R, have been found, and both belong to the G-protein coupled receptor superfamily. In rodents, the MCH1-R is the main transducer of MCH actions, while a functional MCH2-R is not expressed . MCH1-Rs are abundantly expressed in many brain regions (Hervieu et al. 2000; Saito et al. 2001) , including the shell of the Nucleus Accumbens (Nc AccS), the amygdala, the hippocampal formation, the paraventricular nucleus (PVN) of the hypothalamus and monoaminergic nuclei such as the locus coeruleus and the dorsal raphe. Based on this pattern of distribution, MCH1-Rs have been implicated not only in the regulation of Electronic supplementary material The online version of this article (doi:10.1007/s00213-010-1891-y) contains supplementary material, which is available to authorized users. appetite and energy homeostasis but also in stress responses, emotionality, and reward.
Studies using non-peptide MCH1-R antagonists have shown that blocking the MCH1-R has anti-obesity (for a review, see Kowalski and Sasikumar 2007) , anxiolytic (Chaki et al. 2005; Smith et al. 2006) , and antidepressantlike effects in various preclinical models (Borowsky et al. 2002; Chaki et al. 2003) . The effects of the MCH system on feeding and mood-related behaviors have been shown to depend on its activity in the Nc AccS (Georgescu et al. 2005) , a region that has one of the highest MCH1-R expression levels and is also critically involved in drug reward (Wise 2004) . Accordingly, a role of the MCH system on the modulation of cocaine reward was reported recently. MCH, acting through the MCH1-R in the Nc AccS, was shown to increase dopamine responses in vitro and in vivo, whereas MCH1-R antagonists suppressed cocaine self-administration, as well as reinstatement of cocaine-seeking induced by priming doses of the drug, or drug-associated cues (Chung et al. 2009 ). It has also been shown that central administration of MCH increases alcohol intake (Duncan et al. 2005 (Duncan et al. , 2006 . These observations lead us to hypothesize that antagonism of the MCH1-R may modulate rewarding properties of alcohol and the susceptibility to relapse-like behavior.
GW803430 is a potent, non-peptide, brain penetrant MCH1-R antagonist (Hertzog et al. 2006 ). It has previously been shown to decrease food intake and weight in mice, an effect that was absent in animals with disruption of the MCH1-R gene and thus receptor-specific. Additionally, GW803430 showed antidepressant-like activity in the forced swim test and anxiolytic efficacy in the marble burying model in rats. Together, these data support MCH1-R antagonism as a candidate mechanism for treatment of obesity and affective disorders (Gehlert et al. 2009 ). GW803430 has been discontinued from clinical development because of cardiac toxicity but remains a useful research tool because it is potent, selective, orally available, and brain penetrant. Here, we used this tool to examine the potential utility of MCH1-R antagonism in treating alcohol use disorders.
Material and methods

Animals
Male Wistar rats, purchased from Charles River (Wilmington, MA), were used throughout except where specified. Animals were housed two per cage in a temperature and humidity controlled vivarium maintained on a reverse 12 h light/dark cycle, with the light switched off at 7:00A.M. Food and water were available ad libitum except during the initial operant training. Prior to initiating experiments, animals were repeatedly handled. Experiments were conducted during the dark cycle. The experiments were carried out following the National Institutes of Health Guidelines for Care and Use of Laboratory Animals and were approved by the Animal Care and Use Committee of the National Institute on Alcohol Abuse and Alcoholism. Drug GW803430 was synthesized and provided by Eli Lilly and Co (Indianapolis, IN). It was suspended in 10% Tween 80 and saline and administered i.p. in a volume of 1 ml/kg. Doses were based on prior work (Gehlert et al. 2009 ) and receptor occupancy data provided below.
Rat ex vivo autoradiography
Ex vivo autoradiography was performed as described (Gehlert et al. 2009 ). Male Sprague-Dawley rats were administered i.p. with vehicle or GW803430. Forty-five minutes after dosing, rats were decapitated, and the forebrains were removed and stored at −70°C. Twelve micron tissue sections were cut and thaw-mounted onto microscope slides. Slides were incubated in modified Krebs' phosphate buffer with 0.0375% bacitracin (Fluka, Buchs, Switzerland) and 0.4% bovine serum albumin (Sigma-Aldrich), pH 7.4, containing 30 pM 125 I-S036057 (PerkinElmer Life and Analytical Sciences, Waltham, MA; 2200 Ci/mmol) for 90 min at 25°C. Nonspecific binding was assessed by the addition of 10 µM GW803430 to the incubation media. Sections were rinsed twice in buffer, then dipped twice in cold distilled water and dried quickly with a stream of cool air. Sections were exposed with 125 IMicroscale Standards (GE Healthcare, Chalfont St. Giles, UK) on phosphorimaging plates (Fujifilm, Tokyo, Japan) for 3 days. Quantitation was carried out using MCID Elite (MCID, Linton, Cambridge, UK) image analysis. Curve fitting and ED 50 and ED 90 determinations were accomplished using GraphPad Prism software (GraphPad Software Inc., San Diego, CA).
Selectivity of GW803430 was evaluated in vitro. The antagonist was tested at a concentration of 10 µM in a panel of approximately 240 drug targets, specified in Electronic Supplementary Materials, and including receptors, ion channels, and transporters, in assays optimized for each target. Assays were carried out at Cerep (Paris, France) according to published standard protocols available at www.cerep.fr or in house at Lilly Research Laboratories in similar assays.
Operant self-administration training
Training and testing were conducted in operant conditioning chambers housed in sound-attenuating cubicles (Med Associates Inc., Georgia, VT). Each operant chamber was equipped with two retractable levers positioned laterally to a drinking reservoir. Visual stimuli were presented via a light located on the back panel. A microcomputer controlled the delivery of the fluids, presentation of visual stimuli and recording of the behavioral data. Rats were trained to self-administer 10% alcohol (v/v) in 30 min daily sessions on a fixed ratio 1 (FR-1) schedule of reinforcement, in which each response on the active lever resulted in delivery of 0.1 ml of fluid. A response on the second lever had no programmed consequences. For the first 3 days, rats were allowed to lever press for a 0.2% (w/v) saccharin solution and were then trained to self-administer 10% alcohol by fading out the saccharin (Weiss et al. 1993 ).
Alcohol self-administration
Following completion of the saccharin fading procedure, rats (N=8) were trained in 30-min alcohol self-administration sessions under FR-1 schedule over 2 weeks. Following a response that delivered a reinforcer, a 5-s time-out period was in effect, during which house light was on and responses were recorded but not reinforced. Once a stable baseline was established, animals were used to assess the effectiveness of GW803430 (3, 10, 30 mg/kg) using a Latin-square counterbalanced within-subjects design. Test sessions were 4 days apart. Following each test session day, animals were allowed 1 day off, and a new baseline was then established over the following 2 days. Animals received the i.p. injection of drug or vehicle 45-min prior to the self-administration session.
Cue-induced reinstatement of alcohol seeking Rats (N=15) that had reached a robust and stable 10% (v/v) alcohol self-administration upon completion of the saccharin fading procedure continued for 15 days with daily 30-min sessions under an FR-1 schedule of reinforcement and were then used to assess cue-induced reinstatement of alcohol-seeking. Concurrently with the lever pressing, a 5-s time-out period was in effect. A stimulus predictive of alcohol (orange odor) was also presented immediately after the animals were placed in the operant chambers and immediately before the onset of every conditioning session (Cippitelli et al. 2005) . Alcohol-reinforced responding was then extinguished in daily 30-min sessions that continued for 16 days. In this phase, neither alcohol nor house light and orange cues were available. On the day following the last extinction session, a 30-min reinstatement session was carried out without any drug treatment. Odor and cue-light, but not alcohol, were presented, and reinstatement response rates (i.e., responses on the previously alcohol-associated lever) were recorded. These response rates were used to assign animals to treatment groups balanced for response rates for the drug treatment experiment that followed. To assess the effects of GW803430, reinstatement experiments were then conducted every fourth day (on days 5, 9, 13). In a Latin-square counterbalanced order that paralleled that used for the self-administration studies, animals were pretreated with GW803430 (0, 10, 30 mg/kg, i.p.) 45 min prior the onset of the reinstatement sessions. Responding on the inactive lever was also recorded throughout the experiment.
Stress-induced reinstatement of alcohol seeking Stress-induced reinstatement was studied as described previously (Cippitelli et al. 2008) . A separate group of animals (N =32) completed saccharin fading and was subjected to 15 additional alcohol self-administration sessions to establish stable self-administration rates. Responding was then extinguished over 16 daily 30-min sessions during which lever responses activated the delivery mechanism but did not result in the delivery of alcohol. On the day following the extinction phase, animals were subjected to a 15-min electric (0.6 mA current intensity) footshock stress delivered through the grid floor of the chamber under a variable interval 40-s schedule (interval range 10-70 s, duration 0.5 s). After termination of footshock, the levers were extended into the chambers, and responses were recorded for 30 min. Because stressinduced reinstatement cannot be reliably studied repeatedly in the same animal, this experiment used a between subject design, in which the MCH1-R antagonist was injected to separate groups in doses of 0 (N=11), 10 (N=10), and 30 (N=11) mg/kg 30 min prior to each footshock session. Responding on the inactive lever was recorded throughout the experiment.
Taste preference Taste preference was tested as described (Goodwin and Amit 1998) using a two-bottle free choice procedure with continuous access to water or a solution of water with the addition of 0.2% saccharin and 0.001% quinine. Once rats had established a stable consumption of the respective solution, they were treated i.p. with vehicle (N=6) or GW803430 (N=6; 30 mg/kg), and cumulative liquid and food consumption was recorded for the following 24 h.
Locomotor activity
Locomotor activity was assessed using a black square arena (75×50 cm), placed in a dimly lit room. Activity was recorded by a video camera suspended above the field and interfaced with a computerized tracking system, Ethovi-sion® 3 (Noldus Information Technology, Wageningen, The Netherlands). On the first day of the experiment, animals (N=27) were habituated for 10 min to the open field to eliminate the influence of novelty. Drug effects were tested on the following day. Forty-five minutes before open field testing on the second day, animals were treated with GW803430 at doses of 0, 10, and 30 mg/kg (N=9 per group). The software recorded total distance traveled (horizontal activity) and frequency of rearing (vertical activity), as well as number of entries and time spent exploring the central zone of the arena (measures of anxiety).
Loss of righting reflex and alcohol elimination Procedures were as described (Gilpin et al. 2004; Rimondini et al. 2008) . For loss of righting reflex (LORR) assessment, animals (N= 24) were pretreated with GW803430 at doses of 0, 10, and 30 mg/kg (N =8 per group). After 45 min, they were injected i.p. with 3.5 g/kg (20% v/v) alcohol and immediately placed in a supine position in a wire cage lid. The interval between alcohol injection and the time in which the rat was unable to right itself was recorded as the time to lose righting reflex (RR). The time to recover RR was recorded as the time during which the animal was unable to right itself and return to all four paws.
In a separate experiment, animals (N=8) were injected with GW803430 at doses of 0 and 30 mg/kg and then alcohol-treated as described for LORR assessment. Blood samples were taken from the rat tail vein at intervals of 60, 180, and 360 min and analyzed by quantitative gas chromatography.
Statistics
Self-administration data were analyzed using repeated measures one-way analysis of variance (ANOVA) with treatment as the within subject factor, followed up by Newman Keuls post hoc tests. When analyzing the data from cue-and footshock-induced reinstatement, two separate analyses were carried out. A one-way within-subjects ANOVA was performed in vehicle-treated rats (footshock) and in animals subjected to the reinstatement test (cues only) in order to compare response rates on the last day of extinction with those obtained following footshock or cue exposure. The same analysis was used for habituation to the open field in vehicle-treated animals. Treatment effects were analyzed as a within subjects one-way ANOVA for assessment of cue-induced reinstatement and between subject design one-way ANOVA for stress-induced reinstatement. Open field results and LORR were analyzed by one-way ANOVA using the between-subjects factor of treatment (GW803430 dose) whereas kinetics of alcohol elimination were carried out using two-way ANOVA.
Results
Ex vivo autoradiography indicates high central MCH1-R occupancy
This experiment established that behaviorally active doses of GW803430 effectively inhibited the binding of 125 I-S036057 to MCH1 receptors following the i.p. administration and 45 min pretreatment interval used in the present experiments. The binding to three brain regions including the Caudate Putamen, the Nucleus Accumbens shell and core, was assessed. ED 50 and ED 90 for these brain regions are given in Table 1. GW803430 lacks activity in a panel of common drug targets GW803430 did not show activity below 100 nN when tested in vitro in a panel of approximately 240 common drug targets, including receptors, ion channels, and transporters (Table S1 , Electronic Supplementary Materials).
GW803430 suppresses operant alcohol self-administration
The MCH1-R antagonist (3, 10, and 30 mg/kg; Fig. 1 ) dose-dependently suppressed operant responding on the alcohol-reinforced lever (main effect: F (3,21) =15.6; P<0.0001). On post hoc comparison, responding was significantly suppressed at 30 mg/kg (P<0.01) as well as 10 mg/kg (P<0.05), while the 3 mg/kg dose did not differ from vehicle. The 30 mg/kg dose suppressed alcoholreinforced responding by approximately 80%. Responding on the inactive left lever was not significantly affected by the drug (F (3,21) =0.3; NS). Following extinction, a robust increase of responding on the alcohol-associated lever pressing was found when previously alcohol-paired stimuli were reintroduced. Specifically, ANOVA showed a significant difference between responding in the cue-induced reinstatement session and the last one of the extinction phase (F (1,14) =33.4, P<0.0001).
Inactive lever responses also increased significantly, although to a lesser degree (F (1,14) = 12.4, P < 0.01). GW803430 dose-dependently suppressed cue-induced reinstatement (main treatment effect (F (2,28) = 31.4, P < 0.0001)), and post hoc tests showed that both doses tested were active (P<0.01, 10 and 30 mg/kg vs 0 mg/kg, Fig. 2 ). There was also a main effect of treatment on inactive lever responding (F (2,28) =4.8, P<0.05), with post hoc analysis indicating a suppression at both doses used (P<0.05, 10 and 30 mg/kg vs 0 mg/kg). Because both cue presentation and treatment influenced inactive lever responding, which is a potential measure of general (non-directed) activity and response generalization (Shalev et al. 2002) , data were reanalyzed using difference scores (active lever minus inactive lever presses (Le et al. 2005) ). Difference-score analysis replicated the results of the analysis that used raw active lever response rates. This was true both for reinstatement (F (1,14) =28.9, P<0.0001) and for the treatment (F (2,28) =23.0, P<0.0001), establishing that inactive lever responding is unlikely to account for the results.
GW803430 does not significantly affect stress-induced reinstatement of alcohol seeking
Following extinction, a significant footshock-induced reinstatement of alcohol seeking was found, as shown by an increase of lever pressing in the vehicle-treated group on the session preceded by stress compared to the last day of extinction (F (1,10) =9.5, P<0.05). Response rates on the inactive lever were unaffected (F (1,10) =0.2, NS). Although a trend for dose-dependent suppression was noted, blockade of the MCH1-R did not result in a significant attenuation of stress-induced responding on the alcohol-paired lever (main treatment effect: F (2,29) =1.3, NS). Similar to the effect on cue-induced reinstatement, responding on the inactive lever was affected by the drug treatments (main treatment effect: F (2,29) =4.1, P<0.05) at both doses tested (P < 0.05, 10 and 30 mg/kg vs 0 mg/kg, Fig. 3 ). Difference-score analysis produced essentially the same results (data not shown).
GW803430 does not affect taste preference
As shown in Table 2 , total liquid consumption was significantly suppressed by drug treatment (F (1,10) =9.1, P=0.013), in a manner that was highly correlated with, and thus presumably secondary to the expected reduction in feeding (R 2 =0.52, P=0.008). Food intake was, therefore, included as a covariate when analyzing potential drug effects on water or saccharin/quinine solution intake. Controlling for food intake, GW803430 did not significantly affect either water (F (1,9) =0.7; NS) or saccharin/ quinine solution intake (F (1,9) =0.8; NS). Most importantly, preference, expressed as the saccharin/quinine solution consumed as percentage of total fluid intake was unaffected, both when analyzed without co-varying for food intake (F (1,10) =0.6; NS), or when this covariate was included (data not shown). Open-field activity during the 10-min session conducted under habituated conditions is shown in Table 3 . Neither total distance traveled (horizontal activity) nor frequency of rearing (vertical activity) were affected by treatment (main treatment effect: (F (2,24) =0.5, NS) and (F (2,24) =0.02, NS), respectively). Anxiety-related behavioral measures, i.e., the time spent in the central area of the field and the entries into this area, were also unaffected by treatment ((F (2,24) =0.2, NS) and (F (2,24) =0.4, NS), respectively).
GW803430 does not affect alcohol elimination or recovery of the righting reflex
Blood alcohol concentrations decreased over time ( Fig. 4a ; main time effect: F (2,12) =41.9, P<0.0001), but elimination rates were not affected by treatment (main treatment effect: F (1,6) =0.09, NS; time × treatment interaction: F (2,12) =2.7, NS).
Similarly, there was no effect of treatment on time to lose righting reflex (F (2,21) =0.1, NS) or recovery of RR (F (2,21) =0.0, NS, Fig. 4b ).
Discussion
We found that systemic treatment with the MCH1-R antagonist GW803430 dose-dependently decreased operant alcohol self-administration as well as relapse-like behavior induced by exposure to an alcohol-associated cue. In contrast, relapse-like behavior induced by a stressor was not affected. Several observations indicate that these actions are behaviorally and pharmacologically specific. First, locomotor activity was unaffected by the highest GW803430 dose used in the self-administration and reinstatement experiments, making a contribution of nonspecific motor performance impairment unlikely. Second, sensitivity to sedative effects of alcohol, as well as alcohol elimination were unaffected by the drug. Third, taste preference for a saccharin/quinine solution, thought to emulate key properties of the composite sweet and bitter taste of alcohol, was unaffected by the drug. Fourth, GW803430 lacked significant activity in an extensive panel of common drug targets.
GW803430 is potent, highly selective, brain penetrant, and has well documented specific activity in a range of behavioral assays (Gehlert et al. 2009 ). In the present study, ex vivo binding showed nearly complete occupancy of central MCH1-Rs with the route of administration, dose range, and pretreatment intervals used. With the acute treatment used in our study, higher doses than those needed for maximal receptor occupancy at 45 min were needed to produce the behavioral effects. This parallels the recent study in obesity and depression models, where good agreement was observed between doses required for high central receptor occupancy and those needed for behavioral activity following sub-chronic treatment. In contrast, Fig. 3 Administration of GW803430 (0, 10, and 30 mg/kg, i.p.) failed to suppress 0.6 mA footshock-induced reinstatement of alcohol seeking in rats (N=32); active lever (white bars), inactive lever (black bars). Values are the mean (±SEM) number of total responses at both active and inactive levers. +P<0.05, difference in responses on the inactive lever from 0 mg/kg drug treatment; #P<0.05, responses in rats (N=11) exposed to footshock stress (in the absence of reward delivery) compared with the mean number of lever presses of the last day of extinction. For detailed statistics, see "Results." EXT extinction Values are the mean (±SEM) of S+Q (ml), water (ml), total fluid (ml), food intake (g), and preference (%). Preference was calculated separately for each individual and then averaged within each group. *P<0.05 and **P<0.01 significance compared to vehicle (0 mg/kg drug treatment). For detailed statistics, see "Results" approximately 10-fold higher doses were needed with acute dosing (Gehlert et al. 2009 ). The difference in dose requirement on sub-chronic vs acute treatment presumably reflects pharmacokinetic factors, such as a need to saturate the central compartment to produce behavioral effects. Prior data on the role of central MCH in control of alcohol intake are complex. It has been reported that exogenous MCH increased the intake of alcohol as well as a quinine/sucrose solution, at a dose that did not increase the intake of a solution containing sucrose alone (Duncan et al. 2005) . However, in a follow-up study, the same 10 µg intracerebroventricular (i.c.v.) MCH dose robustly increased the breakpoints for self-administration of sucrose, while leaving breakpoints for alcohol unaffected (Duncan et al. 2006) . The latter study also probed the role of MCH signaling in the control of alcohol intake using a peptide MCH analog with selective antagonistic properties at MCH1-Rs in vitro (Bednarek et al. 2002) . Central administration of this antagonist failed to impact the intake of alcohol and also left the intake of an isocaloric sucrose solution unaffected. The antagonist did suppress 2 h chow intake but failed to attenuate MCH-induced alcohol drinking (Duncan et al. 2006) . While the first of these observations may be supportive of in vivo antagonist activity, it is not conclusive, and the lack of efficacy to block effects of exogenous MCH on alcohol drinking suggests that such activity may, at a minimum, be limited, for instance due to limited tissue penetration into some brain areas. Finally, mice with a genetic deletion of MCH1-R have been found to consume more rather than less alcohol compared to wild-type controls (Duncan et al. 2007) , although this is likely confounded by the lean and hyperphagic phenotype of the MCH1-R KO mice Gehlert et al. 2009; Marsh et al. 2002) .
Our findings of a behaviorally specific, dose-dependent, and potent suppression of alcohol self-administration by GW803430, therefore, strongly support a role of endogenous MCH in motivation to obtain and consume alcohol. As indicated above, prior negative findings with MCH1-R antagonism and alcohol intake may be limited by the properties of the peptidergic antagonist used in that study. In addition, the negative findings were obtained using home cage drinking, while we studied the effects of GW803430 under operant conditions thought to more directly assess motivation to obtain the reinforcer. Our present results are, therefore, presumably more closely related to recent data showing that central MCH1-R antagonism suppressed cocaine self-administration and reward and that a genetic deletion of MCH1-R in mice decreased their sensitivity to the rewarding properties of cocaine (Chung et al. 2009 ).
Our reinstatement data further suggest that endogenous MCH signaling is required for reinstatement of alcohol seeking elicited by cues predictive of alcohol availability. Pretreatment with GW803430 potently blocked this relapse-like behavior, whereas footshock-induced reinstatement was not robustly affected. A potential confound in the reinstatement data that needs to be considered is that the MCH1-R antagonist also led to reduced responding on the inactive lever in both cue-and footshock-induced reinstatement. Inactive lever responding is typically interpreted to Values are the mean (±SEM) of distance traveled (cm), rearing behavior (frequency), number of entries into the central area, and time spent in the central area of the arena reflect nonspecific behavioral activity (Shalev et al. 2002) , although it may also reflect response generalization commonly occurring during extinction (Catania 1992 ). An established approach to controlling for the possible influence of these factors is based on an analysis of difference scores, i.e., active lever minus inactive lever responses (Cippitelli et al. 2008; Le et al. 2005) . Application of this analysis to our data appears to make it unlikely that nonspecific factors account for the results. Similar to the self-administration results, our reinstatement data are in agreement with the study by Chung et al (2009) , where blockade of MCH1-Rs reduced relapse to cocaine seeking induced by a priming dose of cocaine itself or cocaine-associated cues, but not by a stressor. In addition, the negative results obtained in our footshockinduced reinstatement experiment parallel recent findings (Nair et al. 2009) , showing that antagonism at MCH1 receptors failed to alter yohimbine-induced reinstatement of food seeking. Previous studies have shown that the mesolimbic dopamine system subserves reinstatement by priming or conditioned stimuli, whereas stress-induced reinstatement involves activity of CRH and noradrenaline systems within the extended amygdala (Kalivas and McFarland 2003; Shaham et al. 2003) . Our present data, therefore, add support to the notion that MCH may be involved in reward regulation (DiLeone et al. 2003; Georgescu et al. 2005; Pissios et al. 2008; Smith et al. 2005) and suggest that the effect of GW803430 to decrease responding for alcohol can potentially be due to modulation of dopamine signaling in the nucleus accumbens by MCH.
Available medications for alcoholism have demonstrated the feasibility of pharmacotherapy in this disorder, but effect sizes are small. In order to address unmet medical needs of this patient population, it is essential to expand the range of treatment options (Bouza et al. 2004; Heilig and Egli 2006) . Neuropeptide systems that modulate stress-, reward-, and feeding-related behaviors may also offer attractive target mechanisms for new alcoholism pharmacotherapies. Our present data strongly suggest that MCH may fall into this category. Although best known for its involvement in energy homeostasis, MCH is also involved in central regulation of both anxiety-and reward-related behaviors (Chung et al. 2009; DiLeone et al. 2003; Georgescu et al. 2005; Pissios et al. 2008; Smith et al. 2005) . MCH1-R antagonism, therefore, potentially could modulate alcohol-related behaviors by acting on positive reinforcement, negative reinforcement, or both. Its selectivity in blocking cue-but not stress-induced reinstatement suggests that modulation of circuitry-mediating alcohol reward is perhaps the most likely mediating mechanism. This would be consistent with microinjection mapping data, which showed that blockade of MCH1-Rs in the shell of the Nucleus Accumbens replicated the effects of systemic antagonist injections on cocaine self-administration and reinstatement (Chung et al. 2009 ).
Alcohol is unique among addictive drugs, in that it is both a pharmacological modulator of brain reward systems and a caloric nutrient. MCH is an important modulator of energy balance and MCH1-R antagonism has been shown to decrease food intake (Gehlert et al. 2009; Morens et al. 2005) , and high-fat food-reinforced operant responding (Nair et al. 2009 ). It is, therefore, likely that the potent suppression of alcohol self-administration observed in our study with an MCH1-R antagonist reflects a combined effect of blocking alcohol reward as well as suppressing appetite for calories. This profile does not in any way diminish the potential of MCH1-R antagonism for treatment of excessive alcohol use and may in fact further increase its attraction.
In summary, we provide here evidence that systemic treatment with a brain penetrant MCH1-R antagonist suppresses alcohol self-administration and cue-induced relapse to alcohol seeking, making this mechanism an attractive target for development of alcoholism pharmacotherapies.
